BioXyTran

Name

BioXyTran

Legal name

Bioxytran, Inc.

Website

https://bioxytraninc.com

Company type

Public

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine) (AFAJAKAG)

Keywords

• Antiviral drug development
• Oxygen therapeutics
• Carbohydrate drug design
• Galectin antagonists
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

Needham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Dietary Supplement Commercial Sales (A-SUQAR): Recurring commercial revenue from A-SUQAR chewable dietary supplement through distribution agreement with Khoury Medical LTD; volume-based marketplace exclusivity potential subject to defined purchase thresholds; marks Bioxytran's transition from development-stage to recurring commercial revenue.
2. Pharmaceutical Pipeline Out-licensing (Future): Future potential revenue from out-licensing of ProLectin-M antiviral and BXT-25 oxygen therapeutic to large pharmaceutical partners; $10 million Joint Venture with Heme Foundation to develop Universal Oxygen Carrier (UOC) as alternative to blood transfusions.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels10 records

Core offering

BioXyTran is a clinical-stage biopharmaceutical company developing carbohydrate-based platform technologies: the Glycovirology platform featuring galectin antagonist antivirals (ProLectin-M, ProLectin-I, ProLectin-A, ProLectin-F, PHM23) targeting viral entry for COVID-19, Long COVID, ARDS, lung fibrosis, influenza and H5N1, and the Hypoxia & Degenerative Diseases platform anchored by BXT-25, an acellular oxygen carrier derived from camel hemoglobin. The company also commercializes A-SUQAR, a chewable partially hydrolyzed guar gum dietary supplement, via a distribution agreement with Khoury Medical LTD.

Product overview

BioXyTran operates a two-platform architecture built around carbohydrate drug design: the Glycovirology platform (galectin antagonist antivirals) and the Hypoxia & Degenerative Diseases platform (oxygen therapeutics). The Glycovirology platform centers on the ProLectin family — ProLectin-M (oral chewable antiviral lead candidate for COVID-19, influenza, and RSV), ProLectin-I (IV formulation for severe/long COVID), ProLectin-A (ARDS treatment), and ProLectin-F (lung fibrosis treatment) — plus PHM23 (galectin antagonist targeting H5N1 bird flu). The Hypoxia & Degenerative Diseases platform is anchored by BXT-25, an investigational acellular oxygen therapeutic derived from camel hemoglobin on a polysaccharide carrier designed to penetrate clots and deliver oxygen to hypoxic brain and tissue. BioXyTran's first commercial product is A-SUQAR, a chewable partially hydrolyzed guar gum dietary supplement distributed via Khoury Medical LTD. The company also holds an exclusive license to the FDA-cleared MDX Viewer tissue metabolic monitoring device, used to evaluate oxygen therapeutics in research and clinical settings.

Differentiator

Problem solved

Functional benefit

Brands

• ProLectin-M: Chewable polysaccharide tablet (galectin antagonist) for early-stage COVID-19 and other viral infections; lead broad-spectrum oral antiviral drug candidate.
• ProLectin-I
• ProLectin-A
• ProLectin-F
• BXT-25
• A-SUQAR
• PHM23

Products and services

• ProLectin-M Oral chewable polysaccharide tablet (galectin antagonist) designed as first-line oral antiviral therapy blocking viral entry into host cells. Reached Phase 1b/2a and Phase 2 trials with 90-100% viral clearance; advancing toward Phase 3 registrational trial in COVID-19, influenza, and RSV. Optimal dose identified as 16,800 mg/day or four tablets per day.
• ProLectin-I Intravenous galectin antagonist formulation for more severe cases of COVID-19 and Long COVID. Binds to the galectin fold of the spike protein to neutralize replication-competent viruses and spike protein fragments thought to cause ongoing inflammation.
• ProLectin-A Galectin antagonist therapy for treatment of Acute Respiratory Distress Syndrome (ARDS) as a result of COVID-19. Designed to reduce trafficking of macrophages responsible for the cytokine storm and restore immune homeostasis.
• ProLectin-F Intravenous galectin antagonist therapy for treatment of lung fibrosis resulting from ventilator use in COVID-19 treatment. Designed to treat organ damage after virus is eliminated from the system.
• BXT-25 Investigational acellular oxygen therapeutic built from stabilized hemoglobin-based molecules derived from FDA-approved camel blood attached to a polysaccharide carrier. Approximately 1/5,000 the size of a red blood cell, enabling oxygen transport and diffusion into tissues where microvascular blood flow is compromised. Targeting stroke, traumatic brain injury, organ ischemia, ARDS, sickle cell disease, wound healing, and neurodegenerative conditions.
• A-SUQAR Chewable dietary supplement containing BioXyTran's proprietary partially hydrolyzed guar gum formulation. Commercialized via distribution agreement with Khoury Medical LTD, representing the company's first recurring commercial revenue product.
• PHM23 Lead galectin antagonist antiviral drug candidate being evaluated against H5N1 avian influenza (bird flu) in collaboration with the University of Georgia under a $100 million USDA HPAI Poultry Innovation Grand Challenge grant. Water-soluble galectin antagonist designed to block viral spike proteins from attaching to host cells.
• MDX Viewer (Tissue Metabolic Score Monitoring) FDA-cleared (510(k)) multiparametric tissue monitoring device (formerly CritiView) licensed exclusively from MDX Life Sciences. Uses minimally invasive multiparametric monitoring via a 3-way Foley catheter to measure NADH redox state, tissue oxygen, cerebral blood flow, and calculate the Tissue Metabolic Score (TMS) as a real-time vital sign for tissue oxygenation monitoring.

Quantifiable outcome

• 100% viral clearance by Day 7 vs placebo (p=0.001) in Phase 2 trial of 38 subjects
• +4 more outcomes

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• University of GeorgiacoreStrategic or Co-development PartnerResearch collaboration to evaluate PHM23 galectin antagonist against H5N1 Highly Pathogenic Avian Influenza virus as part of a potential $100 million USDA HPAI Poultry Innovation Grand Challenge grant. NDA originally signed in March 2025; research led by Dr. Daniela Rajao at UGA's College of Veterinary Medicine. UGA selected PHM23 for inclusion in its grant submission to USDA.
• University of MinnesotacoreStrategic or Co-development PartnerSponsored Research Agreement for advanced biochemical research on polysaccharide and oligosaccharide interactions with biologically relevant targets. Research led by Dr. Kevin Mayo using nuclear magnetic resonance spectroscopy, running through early 2027. University retains IP ownership; Bioxytran receives rights to use resulting data for internal R&D purposes.
• Khoury Medical LTDcoreChannel Partner/ Reseller/ DistributorCommercial Distribution Agreement signed February 17, 2026 to commercialize A-SUQAR, a chewable dietary supplement containing proprietary partially hydrolyzed guar gum formulation, in permitted markets. Represents Bioxytran's transition from development-stage to recurring commercial revenue; initial commercial shipments expected following launch preparations; volume-based marketplace exclusivity potential subject to defined purchase thresholds.
• The Heme FoundationcoreStrategic or Co-development Partner$10 million Joint Venture to develop a Universal Oxygen Carrier (UOC) as an alternative to blood transfusions. Through this JV, Bioxytran secured a long-term source of GMP quality camel hemoglobin — a crucial component for advancing the BXT-25 oxygen transport system. The Heme Foundation is dedicated to solving the world's blood shortages.
• MDX LifeSciences, Inc.coreOEM/ Whitelabel/ Licensing PartnerExclusive licensing agreement for FDA-approved MDX Viewer (formerly CritiView) and OxySense NADH monitoring technology. Provides real-time Tissue Metabolic Score (TMS) biomarker serving as clinical endpoint for measuring oxygen supply to the brain. Used in evaluation of BXT-25 safety and efficacy. Originally FDA-approved monitoring device measuring mitochondrial function and microcirculation hemodynamics.
• Prof. Avraham Mayevsky (scientific advisor and academic collaborator)coreStrategic or Co-development PartnerHead of Bioxytran's Scientific Advisory Board; professor who has collaborated with and advised Bioxytran's scientific network for several decades. Published peer-reviewed articles on Tissue Metabolic Score (TMS) in Journal of Emergency Medicine and Care, American Journal of Cardiovascular and Thoracic Surgery; published 2026 scientific book on Physiological Mapping of the Cerebral Cortex relevant to BXT-25 development. Presented at Targeting Mitochondria World Congress 2019 in Berlin.
• Independent ResearchminorGTM or Marketing PartnerGlobal equity research firm specializing in micro-cap and small-cap public companies; initiated coverage of Bioxytran stock on November 13, 2025, providing investor visibility and third-party research validation.

Scale indicators13 records

Recent moves7 records

Expansion highlights8 records

Direct peers

• Vir Biotechnology: Clinical-stage immunology company developing broad-spectrum antiviral therapies including monoclonal antibodies and small molecules targeting viral entry. Most directly comparable to BioXyTran in pursuing single-platform multi-virus antiviral strategies targeting conserved viral mechanisms rather than single indications.
• HbO2 Therapeutics: Develops Hemopure (HBOC-201), a hemoglobin-based oxygen carrier for surgical and ischemic indications. Most directly comparable to BioXyTran's BXT-25 acellular oxygen carrier platform, with similar mechanism of delivering oxygen to hypoxic tissue via cell-free hemoglobin-based approaches.
• Cocrystal Pharma: Clinical-stage biotechnology company developing broad-spectrum antiviral therapeutics targeting viral replication. Small-cap peer pursuing multi-virus antiviral strategies with platform technology, comparable to BioXyTran's Glycovirology approach.
• Atea Pharmaceuticals: Clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapeutics, including bemnifosbuvir for COVID-19 and other viral infections. Comparable clinical-stage peer pursuing oral antiviral development against the same viral targets as BioXyTran's ProLectin-M.
• Athersys: Clinical-stage biotechnology company developing MultiStem cell therapy for stroke, ARDS, and other ischemic/inflammatory conditions. Comparable small-cap peer pursuing novel therapeutics for the same stroke and ARDS indications targeted by BioXyTran's BXT-25 and ProLectin-A programs.

Broad incumbents

• Pfizer (Paxlovid): Markets Paxlovid (nirmatrelvir/ritonavir), the dominant oral COVID-19 antiviral. BioXyTran explicitly positions ProLectin-M as differentiated versus Paxlovid by targeting viral entry rather than protease inhibition. Pfizer represents the incumbent standard-of-care competitor for BioXyTran's lead asset.
• Merck (Lagevrio/molnupiravir): Markets molnupiravir (Lagevrio), the second major oral COVID-19 antiviral. As a global pharmaceutical incumbent, Merck represents another established competitor in the COVID-19 antiviral space where BioXyTran is positioning ProLectin-M with a differentiated mechanism of action.

Emerging players

• OPK Biotech (Oxyglobin): Developer of Oxyglobin, a hemoglobin-based oxygen carrier approved for veterinary use and explored for human ischemic applications. Comparable to BioXyTran's BXT-25 in pursuing hemoglobin-based oxygen delivery for tissue ischemia, though at a different stage and indication focus.
• Prolong Pharmaceuticals: Develops PEGylated hemoglobin-based oxygen carriers (SANGUINATE) for sickle cell disease and ischemic conditions. Comparable peer in the hemoglobin-based oxygen carrier space competing with BioXyTran's BXT-25 in oxygen therapeutics for hypoxic and ischemic diseases.
• NanoViricides: Clinical-stage company developing nanoviricide antiviral therapeutics that mimic cellular receptors to trap and neutralize viruses. Comparable small-cap platform antiviral peer pursuing broad-spectrum virus neutralization through novel mechanism, similar to BioXyTran's entry-blocking Glycovirology platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/bioxytran
• Facebookfacebook.com/bioxytraninc
• LinkedInlinkedin.com/company/bioxytran-inc
• Instagraminstagram.com/bioxytraninc

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioXyTran